Search Results - "HOULE, S"

Refine Results
  1. 1

    Vaccine hesitancy educational tools for healthcare providers and trainees: A scoping review by Lip, A., Pateman, M., Fullerton, M.M., Chen, H.M., Bailey, L., Houle, S., Davidson, S., Constantinescu, C.

    Published in Vaccine (04-01-2023)
    “…In the era of vaccine hesitancy, highlighted by the current SARS-CoV2 pandemic, there is an acute need to develop an approach to reduce and address…”
    Get full text
    Journal Article
  2. 2

    In vivo evidence for greater amphetamine-induced dopamine release in pathological gambling: a positron emission tomography study with [11C]-(+)-PHNO by Boileau, I, Payer, D, Chugani, B, Lobo, D S S, Houle, S, Wilson, A A, Warsh, J, Kish, S J, Zack, M

    Published in Molecular psychiatry (01-12-2014)
    “…Drug addiction has been associated with deficits in mesostriatal dopamine (DA) function, but whether this state extends to behavioral addictions such as…”
    Get full text
    Journal Article
  3. 3

    Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study by Steeves, T. D. L., Miyasaki, J., Zurowski, M., Lang, A. E., Pellecchia, G., Van Eimeren, T., Rusjan, P., Houle, S., Strafella, A. P.

    Published in Brain (London, England : 1878) (01-05-2009)
    “…Pathological gambling is an impulse control disorder reported in association with dopamine agonists used to treat Parkinson's disease. Although impulse control…”
    Get full text
    Journal Article
  4. 4

    Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD by VAN EIMEREN, T, PELLECCHIA, G, CILIA, R, BALLANGER, B, STEEVES, T. D. L, HOULE, S, MIYASAKI, J. M, ZUROWSKI, M, LANG, A. E, STRAFELLA, A. P

    Published in Neurology (09-11-2010)
    “…Some patients with Parkinson disease (PD) develop pathological gambling when treated with dopamine agonists (DAs). However, little is known about DA-induced…”
    Get full text
    Journal Article
  5. 5

    In-vivo imaging of grey and white matter neuroinflammation in Alzheimer’s disease: a positron emission tomography study with a novel radioligand, [18F]-FEPPA by Suridjan, I, Pollock, B G, Verhoeff, N P L G, Voineskos, A N, Chow, T, Rusjan, P M, Lobaugh, N J, Houle, S, Mulsant, B H, Mizrahi, R

    Published in Molecular psychiatry (01-12-2015)
    “…Our primary aim was to compare neuroinflammation in cognitively intact control subjects and patients with Alzheimer’s disease (AD) by using positron emission…”
    Get full text
    Journal Article
  6. 6

    Elevated fatty acid amide hydrolase in the prefrontal cortex of borderline personality disorder: a [ 11 C]CURB positron emission tomography study by Kolla, Nathan J, Mizrahi, R, Karas, K, Wang, C, Bagby, R M, McMain, S, Simpson, A I, Rusjan, P M, Tyndale, R, Houle, S, Boileau, I

    Published in Neuropsychopharmacology (New York, N.Y.) (01-10-2020)
    “…Amygdala-prefrontal cortex (PFC) functional impairments have been linked to emotion dysregulation and aggression in borderline personality disorder (BPD)…”
    Get full text
    Journal Article
  7. 7

    Serotonin transporter binding is reduced in seasonal affective disorder following light therapy by Tyrer, A. E., Levitan, R. D., Houle, S., Wilson, A. A., Nobrega, J. N., Rusjan, P. M., Meyer, J. H.

    Published in Acta psychiatrica Scandinavica (01-11-2016)
    “…Objective To investigate the effects of light therapy on serotonin transporter binding (5‐HTT BPND), an index of 5‐HTT levels, in the anterior cingulate and…”
    Get full text
    Journal Article
  8. 8

    Light therapy and serotonin transporter binding in the anterior cingulate and prefrontal cortex by Harrison, S. J., Tyrer, A. E., Levitan, R. D., Xu, X., Houle, S., Wilson, A. A., Nobrega, J. N., Rusjan, P. M., Meyer, J. H.

    Published in Acta psychiatrica Scandinavica (01-11-2015)
    “…Objective To investigate the effects of light therapy on serotonin transporter binding (5‐HTT BPND), an index of 5‐HTT levels, in the anterior cingulate and…”
    Get full text
    Journal Article
  9. 9
  10. 10

    Neuroinflammation in healthy aging: A PET study using a novel Translocator Protein 18kDa (TSPO) radioligand, [18F]-FEPPA by Suridjan, I., Rusjan, P.M., Voineskos, A.N., Selvanathan, T., Setiawan, E., Strafella, A.P., Wilson, A.A., Meyer, J.H., Houle, S., Mizrahi, R.

    Published in NeuroImage (Orlando, Fla.) (01-01-2014)
    “…One of the cellular markers of neuroinflammation is increased microglia activation, characterized by overexpression of mitochondrial 18kDa Translocator Protein…”
    Get full text
    Journal Article
  11. 11

    Neuroinflammation in healthy aging: A PET study using a novel Translocator Protein 18 kDa (TSPO) radioligand, [18F]-FEPPA by SURIDJAN, I, RUSJAN, P. M, VOINESKOS, A. N, SELVANATHAN, T, SETIAWAN, E, STRAFELLA, A. P, WILSON, A. A, MEYER, J. H, HOULE, S, MIZRAHI, R

    Published in NeuroImage (Orlando, Fla.) (01-01-2014)
    “…One of the cellular markers of neuroinflammation is increased microglia activation, characterized by overexpression of mitochondrial 18 kDa Translocator…”
    Get full text
    Journal Article
  12. 12

    Stimulation of the Pre-SMA Influences Cerebral Blood Flow in Frontal Areas Involved with Inhibitory Control of Action by Obeso, I, Cho, S.S, Antonelli, F, Houle, S, Jahanshahi, M, Ko, J.H, Strafella, A.P

    Published in Brain stimulation (01-09-2013)
    “…Abstract Selection of the most appropriate response necessitates inhibition of competing or prepotent responses. It is important to characterize which cortical…”
    Get full text
    Journal Article
  13. 13
  14. 14

    Brain serotonin transporter binding in non-depressed patients with Parkinson's disease by Guttman, M., Boileau, I., Warsh, J., Saint-Cyr, J. A., Ginovart, N., McCluskey, T., Houle, S., Wilson, A., Mundo, E., Rusjan, P., Meyer, J., Kish, S. J.

    Published in European journal of neurology (01-05-2007)
    “…Early post‐mortem data suggest that damage to brain serotonin neurones might play a role in some features (e.g., depression) of Parkinson's disease (PD)…”
    Get full text
    Journal Article
  15. 15

    New detection configuration for low activity levels of PET tracers during the analysis of plasma samples by Osovizky, A., Laster, B., Wilson, A.A., Bloomfield, P., Sarusi, B., Vasdev, N., Bell, T., Garcia, A., Houle, S.

    Published in Applied radiation and isotopes (01-09-2019)
    “…A new radio-HPLC detection system for measuring radioactivity in plasma samples during Positron Emission Tomography [PET] studies was developed. It is based on…”
    Get full text
    Journal Article
  16. 16
  17. 17

    Low-frequency component of the heart rate variability spectrum: a poor marker of sympathetic activity by Houle, M S, Billman, G E

    Published in The American journal of physiology (01-01-1999)
    “…The low-frequency component of the heart rate variability spectrum (0.06-0.10 Hz) is often used as an accurate reflection of sympathetic activity. Therefore,…”
    Get full text
    Journal Article
  18. 18

    Protease‐activated receptor‐4: a novel mechanism of inflammatory pain modulation by Asfaha, S, Cenac, N, Houle, S, Altier, C, Papez, M D, Nguyen, C, Steinhoff, M, Chapman, K, Zamponi, G W, Vergnolle, N

    Published in British journal of pharmacology (01-01-2007)
    “…Background and purpose: Protease‐activated receptor‐4 (PAR4), the most recently discovered member of the PARs family, is activated by thrombin, trypsin and…”
    Get full text
    Journal Article
  19. 19

    Changes in Regional Brain Glucose Metabolism Measured With Positron Emission Tomography After Paroxetine Treatment of Major Depression by Kennedy, Sidney H., Evans, Kenneth R., Krüger, Stephanie, Mayberg, Helen S., Meyer, Jeffrey H., McCann, Sonia, Arifuzzman, Andrew I., Houle, Sylvain, Vaccarino, Franco J.

    Published in The American journal of psychiatry (01-06-2001)
    “…OBJECTIVE: Depression is commonly associated with frontal hypometabolic activity accompanied by hypermetabolism in certain limbic regions. It is unclear…”
    Get full text
    Journal Article
  20. 20

    Occupancy of Serotonin Transporters by Paroxetine and Citalopram During Treatment of Depression: A [11C]DASB PET Imaging Study by Meyer, Jeffrey H., Wilson, Alan A., Ginovart, Nathalie, Goulding, Verdell, Hussey, Doug, Hood, Karen, Houle, Sylvain

    Published in The American journal of psychiatry (01-11-2001)
    “…OBJECTIVE: Selective serotonin reuptake inhibitors are commonly used to treat major depression; however, the percentage of serotonin (5-HT) transporter (5-HTT)…”
    Get full text
    Journal Article